Technology, Healthcare May 27, 2021 04:06 PM (GMT+8) · EqualOcean
Kaipu biological announced that it is estimated that the net profit attributable to shareholders of Listed Companies in the first half of 2021 will be 320-370 million yuan, with a year-on-year growth of 148.09% - 186.85%. The company's medical laboratories (including Hong Kong) actively participated in epidemic prevention and control and strengthened capacity-building. The revenue of detection services has achieved rapid growth, and the demand for nucleic acid detection has increased, which has brought sales impetus to the company's main products, supporting instruments and consumables. During the reporting period, the company's main business income has achieved rapid growth, driving the rapid growth of the company's performance.
Related companies: